Cas9 Stable Cell Line - JeKo-1

The JeKo-1-Cas9 stable cell line is an important immunological model established by integrating the Cas9 nuclease into the JeKo-1 mantle cell lymphoma (MCL) background. The JeKo-1 cell line was initially isolated from peripheral blood mononuclear cells of a 78-year-old female patient with large cell MCL who had undergone leukemic transformation. These cells exhibited a typical B-cell phenotype (IgM+, CD5+, CD19+) and were characterized by the t(11;14)(q13;q32) translocation, which leads to the hallmark overexpression of cyclin D1. The stable expression of Cas9 in this cell line provides a highly reproducible platform for genome editing, overcoming the challenge of low transfection efficiency commonly found in suspension-cultured lymphocytes. This system enables precise and scalable manipulation of the MCL genome, thereby facilitating research on B-cell signaling and the identification of genetic vulnerability in aggressive lymphomas.

In research, the JeKo-1-Cas9 stable cell line is primarily used for drug development and research into the molecular pathogenesis of mantle cell lymphoma. It is a powerful CRISPR gene-editing screening tool that can be used to identify genes involved in cell cycle regulation, apoptosis, and resistance to B-cell receptor (BCR) pathway inhibitors or Bcl-2 antagonists. Researchers use this cell line to construct targeted knockout models of oncogenic driver genes or tumor suppressor genes, thereby gaining a deeper understanding of the mechanisms of lymphoma development and treatment failure. Furthermore, due to its high tumorigenicity in immunodeficient animal models, JeKo-1-Cas9 is also an important model for immunotherapy research, used to evaluate the cytotoxicity of CAR-T cells and develop bispecific antibodies.